与VC或海外资本相比，国有资本在支持创新药产业方面有明显优势。首先是资金来源相对稳定、期限更长，更有条件支持长期研发项目；其次，政府资本高度契合国家战略方向，在推动关键核心技术攻关、培育新兴产业和未来产业方面具有更强的政策协同能力；第三，政府资本可以通过基金撬动社会资本，发挥放大效应，带动更多市场化资金进入生物医药领域。但同时也要看到，国有资本在市场化投资经验、专业化判断以及决策效率方面，与一些成熟的市场化VC相比仍有提升空间。如果投资决策过于保守或者流程过长，也可能错失一些创新机会。
另一方面，坚持质量导向，严把发行上市准入关。从国家科技自立自强战略整体布局考虑，深化对“硬科技”的认识与理解，积极发挥科创板服务新质生产力发展功能；用好与国家相关主管部门的常态化协作机制，精准识别“硬科技”企业。更好统筹投资与融资协调发展，压实中介机构“看门人”责任，坚决防止科技创新能力不突出、市场前景不明朗的劣质企业闯关上市，努力引导有限的上市资源真正用于支持科技创新。这也是切实保护投资者合法权益的必然要求。，详情可参考新收录的资料
，推荐阅读新收录的资料获取更多信息
Boris Cherny, creator of Claude Code, still starts 80% of tasks in plan mode today. But with each new model generation, the one-shot success rate after planning keeps climbing. I think we're approaching the point where plan mode as a separate human-in-the-loop step fades away. Not because planning doesn't matter, but because models are getting good enough to plan well on their own. Big caveat: this only works if you've done the work in levels 3 through 6. If your context is clean, your constraints are explicit, your tools are well-described, and your feedback loops are tight, the model can plan reliably without you reviewing it first. If you haven't done that work, you'll still need to babysit the plan.，推荐阅读新收录的资料获取更多信息
pdf = Prawn::Document.new do